» Articles » PMID: 34884423

Natural History of a Mouse Model Overexpressing the Dp71 Dystrophin Isoform

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Dec 10
PMID 34884423
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Dystrophin is a 427 kDa protein that stabilizes muscle cell membranes through interactions with the cytoskeleton and various membrane-associated proteins. Loss of dystrophin as in Duchenne muscular dystrophy (DMD) causes progressive skeletal muscle weakness and cardiac dysfunction. Multiple promoters along the dystrophin gene () give rise to a number of shorter isoforms. Of interest is Dp71, a 71 kDa isoform implicated in DMD pathology by various animal and patient studies. Strong evidence supporting such a role for Dp71, however, is lacking. Here, we use del52;WT mice to understand how Dp71 overexpression affects skeletal and cardiac muscle phenotypes. Apart from the mouse gene, del52;WT mice are heterozygous for a full-length, exon 52-deleted human transgene expected to only permit Dp71 expression in muscle. Thus, del52;WT mice overexpress Dp71 through both the human and murine dystrophin genes. We observed elevated Dp71 protein in del52;WT mice, significantly higher than wild-type in the heart but not the tibialis anterior. Moreover, del52;WT mice had generally normal skeletal muscle but impaired cardiac function, exhibiting significant systolic dysfunction as early as 3 months. No histological abnormalities were found in the tibialis anterior and heart. Our results suggest that Dp71 overexpression may have more detrimental effects on the heart than on skeletal muscles, providing insight into the role of Dp71 in DMD pathogenesis.

Citing Articles

Efficacy of exon-skipping therapy for DMD cardiomyopathy with mutations in actin binding domain 1.

Shiba N, Yang X, Sato M, Kadota S, Suzuki Y, Agata M Mol Ther Nucleic Acids. 2023; 34:102060.

PMID: 38028197 PMC: 10654596. DOI: 10.1016/j.omtn.2023.102060.


mRNA in situ hybridization exhibits unbalanced nuclear/cytoplasmic dystrophin transcript repartition in Duchenne myogenic cells and skeletal muscle biopsies.

Falzarano M, Mietto M, Fortunato F, Farne M, Martini F, Ala P Sci Rep. 2023; 13(1):15942.

PMID: 37743371 PMC: 10518324. DOI: 10.1038/s41598-023-43134-6.


CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein.

Egorova T, Polikarpova A, Vassilieva S, Dzhenkova M, Savchenko I, Velyaev O Mol Ther Methods Clin Dev. 2023; 30:161-180.

PMID: 37457303 PMC: 10339130. DOI: 10.1016/j.omtm.2023.06.006.


Nuclear Small Dystrophin Isoforms during Muscle Differentiation.

Donandt T, Todorow V, Hintze S, Graupner A, Schoser B, Walter M Life (Basel). 2023; 13(6).

PMID: 37374149 PMC: 10302385. DOI: 10.3390/life13061367.

References
1.
Desgeorges T, Liot S, Lyon S, Bouviere J, Kemmel A, Trignol A . Open-CSAM, a new tool for semi-automated analysis of myofiber cross-sectional area in regenerating adult skeletal muscle. Skelet Muscle. 2019; 9(1):2. PMC: 6323738. DOI: 10.1186/s13395-018-0186-6. View

2.
Tamiyakul H, Kemter E, Kosters M, Ebner S, Blutke A, Klymiuk N . Progressive Proteome Changes in the Myocardium of a Pig Model for Duchenne Muscular Dystrophy. iScience. 2020; 23(9):101516. PMC: 7495112. DOI: 10.1016/j.isci.2020.101516. View

3.
Sarig R, Gitelman I, Davis C, Fuchs O, Yaffe D, Nudel U . Targeted inactivation of Dp71, the major non-muscle product of the DMD gene: differential activity of the Dp71 promoter during development. Hum Mol Genet. 1999; 8(1):1-10. DOI: 10.1093/hmg/8.1.1. View

4.
Leibovitz S, Meshorer A, Fridman Y, Wieneke S, Jockusch H, Yaffe D . Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle. Neuromuscul Disord. 2002; 12(9):836-44. DOI: 10.1016/s0960-8966(02)00141-4. View

5.
Yavas A, Weij R, van Putten M, Kourkouta E, Beekman C, Puolivali J . Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model. PLoS One. 2020; 15(12):e0244215. PMC: 7757897. DOI: 10.1371/journal.pone.0244215. View